NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiovascular disease, centered on obicetrapib and related formulations. The company is organized under Dutch law with operations and commercial planning tied to the United States and partnered European markets.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment-stage cardiovascular therapies, primarily obicetrapib and related formulations.
License rights granted to Menarini for commercialization in defined territories.
Sale of obicetrapib tablets and active pharmaceutical ingredients to Menarini.
Asiakkaat
The company’s primary commercial counterparty is Menarini, which holds rights to commercialize obicetrapib in most European countries if approved. In the United States, the intended end customers are patients with high cardiovascular risk and residual elevated LDL-C, reached through physicians and specialty channels after regulatory approval.
Buys license rights and product supply for commercialization in most European territories.
Prescribe obicetrapib if approved for patients needing additional LDL-C lowering.
End users targeted for oral therapy after standard lipid-lowering treatment.
May handle distribution and fulfillment outside the U.S. or in selected regions.
Potential collaborators for Japan, China, and other non-core markets.
Strategia
The company’s strategy is to advance obicetrapib through late-stage development, seek regulatory approval, and build commercialization capabilities in the United States. Outside the U.S., it relies on partnering, with Menarini serving as the key European commercialization partner and additional collaborations considered for other regions.
Approval is required before the company can generate meaningful product sales.
The company intends to sell in the U.S. itself and needs sales and distribution infrastructure.
Partnering can extend reach while limiting the need to build local infrastructure everywhere.
Additional candidates can diversify the company beyond a single lead asset.
Maantiede
NewAmsterdam Pharma is incorporated in the Netherlands, with a registered office in Naarden and a U.S. agent subsidiary in Florida. Commercial rights for obicetrapib cover the majority of European countries through Menarini, while the company plans to pursue U.S. commercialization itself and evaluate partners for Japan, China, and other jurisdictions.
Riskit
The company depends heavily on successful development and approval of a single lead asset, so clinical, regulatory, and commercialization setbacks could materially impair value. As a clinical-stage business with limited operating history, it also faces financing, execution, intellectual property, and partner-dependence risks typical of drug developers.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company has no approved products and relies on obicetrapib's trial results.
Kohdistuu: BROADWAY and TANDEM programs
- Regulatory approval delay or denialVaikutus: KorkeaTodennäköisyys: Kohtalainen
Revenue depends on obtaining marketing authorization before commercialization.
Kohdistuu: FDA and ex-U.S. regulators
- Partner concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
Menarini is the key European commercialization counterparty and supply customer.
Kohdistuu: License and supply agreements
- Intellectual property and patent riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Future value depends on protecting obicetrapib from generic or legal challenges.
Kohdistuu - Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company expects continued losses and may need external capital.
Kohdistuu - Commercial execution riskVaikutus: KorkeaTodennäköisyys: Matala
The company has limited internal sales and marketing infrastructure.
Kohdistuu: U.S. launch and partner-managed territories
Kirjanpito
Harkinnanvaraiset erätUpfront fees and ongoing obligations are allocated between license and R&D services.
Vaikutus: Affects timing of revenue recognition and deferred revenue balances
Menarini supply pricing includes a markup on actual costs and estimate updates.
Vaikutus: Can cause quarter-to-quarter revenue variability
Recognition depends on whether future payments are considered highly probable.
Vaikutus: Can shift revenue between periods
R&D costs rely on estimates for CROs, sites, and investigator services.
Vaikutus: Affects operating expense timing and comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Novo Nordisk A/S
NVO · Pharmaceutical Preparations
Novo Nordisk A/S is a Denmark-based pharmaceutical company focused on medicines for diabetes, obesity, and other serious chronic diseases.
Tenax Therapeutics, Inc
TENX · Pharmaceutical Preparations
Pharvaris N.V.
PHVS · Pharmaceutical Preparations
Amarin Corporation plc
AMRN · Pharmaceutical Preparations
Amarin Corporation plc is a pharmaceutical company centered on cardiovascular risk reduction therapies, with its business largely built around a single branded product, VASCEPA (icosapent ethyl).
Larimar Therapeutics, Inc.
LRMR · Pharmaceutical Preparations
Ligand Pharmaceuticals Incorporated
LGND · Pharmaceutical Preparations
Ligand Pharmaceuticals is a biopharmaceutical royalty company that acquires, finances, and licenses rights to high-value medicines rather than developing drugs itself.
Päivitetty: 24.9.2026